Indacaterol (maleate)

Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder) . Indacaterol maleate can also be used in cardiovascular disease research[1][2].

Product Specifications

CAS Number

[753498-25-8]

Product Name Alternative

QAB149

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Cancer; Endocrinology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Indacaterol-maleate.html

Purity

99.82

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1NC2=C(C([C@@H](O)CNC3CC4=C(C=C(CC)C(CC)=C4)C3)=CC=C2O)C=C1.O=C(O)/C=C\C(O)=O

Molecular Formula

C28H32N2O7

Molecular Weight

508.56

Precautions

H302, H315, H319, H335

References & Citations

[1]Lee SU, et al. Indacaterol inhibits tumor cell invasiveness and MMP-9 expression by suppressing IKK/NF-κB activation. Mol Cells. 2014 Aug;37 (8) :585-91. |[2]Calzetta L, et al. Effects of the new ultra-long-acting β2-AR agonist indacaterol in chronic treatment alone or in combination with the β1-AR blocker metoprolol on cardiac remodelling. 2015.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

β adrenergic receptor

Citation 01

Pharmaceutics. 2020 Feb 11;12 (2) :145.|bioRxiv. 2025 May 29:2025.05.28.656715.|Drug Test Anal. 2021 Feb;13 (2) :283-298.|J Chromatogr A. 2024 Feb 22:1717:464696.|J Neuroimmunol. 2019 Jul 15:332:37-48.